Identification of WEE1 as a target to make AKT inhibition more effective in melanoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29. doi:10.3322/caac.21254. PMID:25559415
   PubMed Web of Science ®Google Scholar
• Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008;68:3429-39. doi:10.1158/0008-5472.CAN-07-5867. PMID:18451171
   PubMed Web of Science ®Google Scholar
• Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010;19:1355-66. doi:10.1517/13543784.2010.520701. PMID:20846000
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Flaherty KT. BRAF in Melanoma: Pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer. 2011;2011:423239. doi:10.1155/2011/423239. PMID:22175026
   PubMedGoogle Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19. doi:10.1056/NEJMoa1002011. PMID:20818844
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16. doi:10.1056/NEJMoa1103782. PMID:21639808
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65. doi:10.1016/S0140-6736(12)60868-X. PMID:22735384
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-14. doi:10.1056/NEJMoa1203421. PMID:22663011
   PubMed Web of Science ®Google Scholar
• Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH, Shin SY. The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 2011;413:311-7. doi:10.1016/j.bbrc.2011.08.093. PMID:21889492
   PubMed Web of Science ®Google Scholar
• Masuda S, Izpisua Belmonte JC. Trametinib for patients with advanced melanoma. Lancet Oncol. 2012;13:e409; author reply e-10. doi:10.1016/S1470-2045(12)70419-9. PMID:23026823
   PubMed Web of Science ®Google Scholar
• Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015;35:177-86. doi:10.14694/EdBook_AM.2015.35.177
   Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-7. doi:10.1038/nature09626. PMID:21107323
   PubMed Web of Science ®Google Scholar
• Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci U S A. 2015;112:E536-45. doi:10.1073/pnas.1418163112. PMID:25624498
   PubMed Web of Science ®Google Scholar
• Delmas A, Cherier J, Pohorecka M, Medale-Giamarchi C, Meyer N, Casanova A, Sordet O, Lamant L, Savina A, Pradines A, et al. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. Oncotarget. 2015;6:15250-64. doi:10.18632/oncotarget.3888. PMID:26098773
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71:2750-60. doi:10.1158/0008-5472.CAN-10-2954. PMID:21317224
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-95. doi:10.1016/j.ccr.2010.11.023. PMID:21156289
   PubMed Web of Science ®Google Scholar
• Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PloS One. 2011;6:e28973. doi:10.1371/journal.pone.0028973. PMID:22194965
   PubMed Web of Science ®Google Scholar
• Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 2014;13:83. doi:10.1186/1476-4598-13-83. PMID:24735930
   PubMed Web of Science ®Google Scholar
• Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29:4688-95. doi:10.1200/JCO.2011.35.5263. PMID:22025163
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Wulf GM, Barry W, Birrer MJ, Westin SN, Quy P, Bell-McGuinn KM, Lasonde B, Whalen C, Aghajanian C, Solit DB, Mills GB, Cantley L, and Winer EP, et al. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). J of Clin Oncol. 2014;32(15_suppl):2510-2510. doi:10.1200/jco.2014.32.15_suppl.2510.
   Web of Science ®Google Scholar
• Algazi AP, Muthukumar AH, O'Brien K, Lencioni A, Tsai KK, Kadafour M, Chapman PB, Daudet A, et al. Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma. J of Clin Oncol. 2015;33(15_suppl):9068-9068. doi:10.1200/jco.2015.33.15_suppl.9068.
   Google Scholar
• Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 1995;14:1878-91. PMID:7743995
   PubMed Web of Science ®Google Scholar
• Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol. 2013;182:1151-62. doi:10.1016/j.ajpath.2012.12.019. PMID:23416158
   PubMed Web of Science ®Google Scholar
• Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 2006;66:8200-9. doi:10.1158/0008-5472.CAN-06-0809. PMID:16912199
   PubMed Web of Science ®Google Scholar
• Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005;65:2412-21. doi:10.1158/0008-5472.CAN-04-2423. PMID:15781657
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Sharma A, Gowda R, Robertson GP. Identification of glycogen synthase kinase 3alpha as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2013;26:886-99. doi:10.1111/pcmr.12156. PMID:24034838
   PubMed Web of Science ®Google Scholar
• Trapnell C, Pachter L, Salzberg SL. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105-11. doi:10.1093/bioinformatics/btp120. PMID:19289445
   PubMed Web of Science ®Google Scholar
• Gowda R, Kardos G, Sharma A, Singh S, Robertson GP. Nanoparticle based celecoxib and plumbagin for the synergistic treatment of melanoma. Mol Cancer Ther. 2017;16(3):440-52. doi: 10.1158/1535-7163.MCT-16-0285. PMID:28003325.
   PubMed Web of Science ®Google Scholar
• Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP. Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther. 2014;13:1679-89. doi:10.1158/1535-7163.MCT-13-0867. PMID:24688050
   PubMed Web of Science ®Google Scholar
• Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP. Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther. 2014;13:2328-40. doi:10.1158/1535-7163.MCT-14-0357. PMID:25082958
   PubMed Web of Science ®Google Scholar
• Gowda R, Sharma A, Robertson GP. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. Cancer Lett. 2017;385:243-50. doi:10.1016/j.canlet.2016.10.016. PMID:27769779
   PubMed Web of Science ®Google Scholar
• Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014;13:1690-703. doi:10.1158/1535-7163.MCT-13-0868. PMID:24688051
   PubMed Web of Science ®Google Scholar
• Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008;68:7638-49. doi:10.1158/0008-5472.CAN-07-6614. PMID:18794153
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55. doi:10.1016/0065-2571(84)90007-4. PMID:6382953
   PubMedGoogle Scholar
• Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002-10. doi:10.1158/0008-5472.CAN-04-1399. PMID:15466193
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007;67:3626-36. doi:10.1158/0008-5472.CAN-06-4234. PMID:17440074
   PubMed Web of Science ®Google Scholar
• Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem biol. 2012;8:905-12. doi:10.1038/nchembio.1085. PMID:23023260
   PubMed Web of Science ®Google Scholar
• Dominguez-Kelly R, Martin Y, Koundrioukoff S, Tanenbaum ME, Smits VA, Medema RH, Debatisse M, Freire R. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol. 2011;194:567-79. doi:10.1083/jcb.201101047. PMID:21859861
   PubMed Web of Science ®Google Scholar
• Hu MG, Deshpande A, Enos M, Mao D, Hinds EA, Hu GF, Chang R, Guo Z, Dose M, Mao C, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009;69:810-8. doi:10.1158/0008-5472.CAN-08-2473. PMID:19155308
   PubMed Web of Science ®Google Scholar
• Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PloS One. 2013;8:e57523. doi:10.1371/journal.pone.0057523. PMID:23520471
   PubMed Web of Science ®Google Scholar
• Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: A function for each cell compartment? Trends Cell Biol. 2003;13:65-70. doi:10.1016/S0962-8924(02)00043-0. PMID:12559756
   PubMed Web of Science ®Google Scholar
• Xu N, Hegarat N, Black EJ, Scott MT, Hochegger H, Gillespie DA. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol. 2010;190:297-305. doi:10.1083/jcb.201003004. PMID:20679434
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell. 2007;129:1261-74. doi:10.1016/j.cell.2007.06.009. PMID:17604717
   PubMed Web of Science ®Google Scholar
• Khwaja A. Akt is more than just a Bad kinase. Nature. 1999;401:33-4. doi:10.1038/43354. PMID:10485701
   PubMed Web of Science ®Google Scholar
• Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002;22:7831-41. doi:10.1128/MCB.22.22.7831-7841.2002. PMID:12391152
   PubMed Web of Science ®Google Scholar
• Nissan MH, Solit DB. The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep. 2011;13:479-87. doi:10.1007/s11912-011-0198-4. PMID:21997758
   PubMed Web of Science ®Google Scholar
• Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18:244-57. doi:10.1016/j.ccr.2010.08.011. PMID:20832752
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A. 1999;96:1002-7. doi:10.1073/pnas.96.3.1002. PMID:9927683
   PubMed Web of Science ®Google Scholar
• Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797-808. doi:10.1038/sj.onc.1207532. PMID:15077143
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501. doi:10.1038/nrc839. PMID:12094235
   PubMed Web of Science ®Google Scholar
• King FW, Skeen J, Hay N, Shtivelman E. Inhibition of Chk1 by activated PKB/Akt. Cell Cycle. 2004;3:634-7. doi:10.4161/cc.3.5.894. PMID:15107605
   PubMed Web of Science ®Google Scholar
• Tonic I, Yu WN, Park Y, Chen CC, Hay N. Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J Biol Chem. 2010;285:23790-8. doi:10.1074/jbc.M110.104372. PMID:20495005
   PubMed Web of Science ®Google Scholar
• Xu N, Lao Y, Zhang Y, Gillespie DA. Akt: A double-edged sword in cell proliferation and genome stability. J Oncol. 2012;2012:951724. doi:10.1155/2012/951724. PMID:22481935
   PubMedGoogle Scholar
• Kasahara K, Goto H, Izawa I, Kiyono T, Watanabe N, Elowe S, Nigg EA, Inagaki M. PI 3-kinase-dependent phosphorylation of Plk1-Ser99 promotes association with 14-3-3 gamma and is required for metaphase-anaphase transition. Nat Commun. 2013;4:1882. doi:10.1038/ncomms2879. PMID:23695676
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A. 2003;100:5789-94. doi:10.1073/pnas.1031523100. PMID:12732729
   PubMed Web of Science ®Google Scholar
• Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847-59. doi:10.1038/nrc2223. PMID:17943136
   PubMed Web of Science ®Google Scholar
• Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388:1257-74. doi:10.1515/BC.2007.159. PMID:18020943
   PubMed Web of Science ®Google Scholar
• Luke JJ, Hodi FS. Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma. Clin Cancer Res. 2012;18:9-14. doi:10.1158/1078-0432.CCR-11-2197. PMID:22083257
   PubMed Web of Science ®Google Scholar